Literature DB >> 9132076

Role of catheter ablation for atrial fibrillation.

M Haïssaguerre1, D C Shah, P Jaïs, J Clémenty.   

Abstract

Atrial fibrillation, the most common of all sustained cardiac arrhythmias, can be cured using extensive surgical atriotomies. Experimental studies using linear radiofrequency catheter ablation lesions suggest the relative safety and high efficacy of these procedures. However animal models may not be relevant to human pathology because of the small size of atria, different pathophysiologic substrates, and the lack of data pertaining to spontaneous initiation of atrial fibrillation. Preliminary human studies show a higher success rate when linear ablations are performed in the left atrium than in the right atrium and that arrhythmogenic foci play a significant role in atrial fibrillation. However the procedures are prolonged, and it is difficult with current technology to achieve a linear conduction block consistently. The challenge remains to optimize this as yet investigational technique and transform it into a routine procedure.

Entities:  

Mesh:

Year:  1997        PMID: 9132076     DOI: 10.1097/00001573-199701000-00004

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  4 in total

1.  The effect of a residual isthmus of surviving tissue on conduction after linear ablation in atrial myocardium.

Authors:  S P Thomas; E M Wallace; D L Ross
Journal:  J Interv Card Electrophysiol       Date:  2000-04       Impact factor: 1.900

Review 2.  Endocavitary treatment of atrial fibrillation.

Authors:  S B Olsson; E I Hertervig; O Kongstad; C Meurling; S Yuan
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

Review 3.  Is there a future for antiarrhythmic drug therapy?

Authors:  P G Guerra; M Talajic; D Roy; M Dubuc; B Thibault; S Nattel
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

Review 4.  Cost effectiveness of therapies for atrial fibrillation. A review.

Authors:  M P Teng; L E Catherwood; D P Melby
Journal:  Pharmacoeconomics       Date:  2000-10       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.